AZN - AstraZeneca PLC
39.47 -0.02 (-0.05%)
After hours: 4:26PM EDT
| Previous Close | 39.21 |
| Open | 39.67 |
| Bid | 38.30 x 1100 |
| Ask | 39.80 x 4000 |
| Day's Range | 39.26 - 39.72 |
| 52 Week Range | 31.99 - 40.16 |
| Volume | 4,488,564 |
| Avg. Volume | 4,119,217 |
| Market Cap | 99.421B |
| Beta (3Y Monthly) | 0.53 |
| PE Ratio (TTM) | 37.43 |
| EPS (TTM) | 1.05 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.40 (3.59%) |
| Ex-Dividend Date | 2018-08-09 |
| 1y Target Est | 41.66 |
- Yahoo Finance Video•6 days ago
Drug commercials you see on TV may be overhauled
Pharmaceutical companies could soon be required to include the list price of medicines in their TV ads. Yahoo Finance’s Alexis Christoforous and Sibile Marcellus discuss the details.
- Motley Fool•4 hours ago
Why Tesaro, Inc. Is Tanking Today
Good news for a rival drug translates to bad news for Tesaro.
- Market Realist•6 hours ago
How Novartis’s Business Segments Performed in the Third Quarter
As discussed earlier, Novartis (NVS) missed Wall Street analysts’ estimates for revenues with reported revenues of ~$12.78 billion during the third quarter of 2018, a 2.9% increase in YoY revenues. Novartis AG is the holding company providing healthcare solutions, and its business is classified into three business segments including the Innovative Medicines segment, Sandoz, and Alcon. The below chart shows the revenue performance of Novartis’s segments since the first quarter of 2017.
- Motley Fool•7 hours ago
Here's Why Clovis Oncology Dropped as Much as 21.2% Today
The biopharma stock fell on excellent news -- for the competition.
- Business Wire•14 hours ago
AstraZeneca to Present New Data Demonstrating Breadth of Research Portfolio in Renal Disease at ASN Kidney Week 2018
35 scientific data presentations and publications, including new evidence for LOKELMA™ in hyperkalemia and FARXIGA® on renal endpoi
- Business Wire•yesterday
Solo-1 Phase III Trial Demonstrates Lynparza Maintenance Therapy Cut the Risk of Disease Progression or Death by 70% in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer
60% of patients receiving LYNPARZA remained progression-free at three years compared to 27% on placebo following platinum-based chemotherapy
- Reuters•yesterday
AstraZeneca's Lynparza shown to put brakes on ovarian cancer
An AstraZeneca drug that blocks a cancer cell's ability to repair its genetic code greatly reduced the risk of ovarian cancer worsening in a phase III trial, underpinning its lead against two U.S. rivals in the same class. Given as a maintenance therapy to reinforce initial chemotherapy, Lynparza halted or reversed tumour growth in 60 percent of patients three years into the trial. At year four, the progression-free survival (PFS) rate in the Lynparza group was still above 50 percent, against 11 percent for chemotherapy alone.
- Zacks•3 days ago
The Zacks Analyst Blog Highlights: AstraZeneca, salesforce, Mastercard, Lam Research and Koninklijke
The Zacks Analyst Blog Highlights: AstraZeneca, salesforce, Mastercard, Lam Research and Koninklijke
- Motley Fool•5 days ago
2 Big Pharmas Pleased With J&J's Third-Quarter Earnings Report
Johnson & Johnson's latest earnings report suggests pricing concerns in the U.S. are overblown for pharmaceutical stocks with strong oncology exposure. Here's what you need to know.
- Yahoo Finance•6 days ago
Big pharma: Trump rule mandating drug prices in TV ads might be unconstitutional
The Trump new administration's proposal to require prescription drug manufacturers to disclose prices in TV ads may be primed for legal challenges.
- Zacks•6 days ago
AstraZeneca's (AZN) Lynparza Gets Another Orphan Drug Status
AstraZeneca (AZN) and partner Merck's Lynparza receive Orphan Drug designation (ODD) by the FDA for the treatment of pancreatic cancer.
- Reuters•7 days ago
May says Irish backstop can't derail deadlocked Brexit talks
Prime Minister Theresa May urged the EU on Monday not to allow a stand-off over a 'backstop' for Ireland to derail Brexit talks, saying she believed a deal was still achievable as a top EU official said chances of a no-deal divorce had increased. Addressing a rowdy session of parliament before she headed to Brussels for a summit on Wednesday, May remained upbeat but repeated she would not agree to anything that could split the United Kingdom.
- Reuters•7 days ago
AstraZeneca will keep UK investment freeze if no Brexit clarity
AstraZeneca will keep its freeze on manufacturing investments in Britain if the country's exit from the European Union fails to give enough clarity on future trading relations, the drugmaker's chairman was quoted as saying on Monday. The comments add to pressure on British Prime Minister Theresa May to rethink her plan for leaving the EU after Brexit talks reached a stand-off at the weekend over arrangements for the UK border with Ireland. "If a transition deal does not make clear what will happen in the future, we will maintain our decision not to invest," Leif Johansson told France's Le Monde newspaper.
Reuters•7 days agoAstraZeneca will keep UK investment freeze if no Brexit clarity
AstraZeneca (AZN.L) will keep its freeze on manufacturing investments in Britain if the country's exit from the European Union fails to give enough clarity on future trading relations, the drugmaker's chairman was quoted as saying on Monday. The comments add to pressure on British Prime Minister Theresa May to rethink her plan for leaving the EU after Brexit talks reached a stand-off at the weekend over arrangements for the UK border with Ireland. "If a transition deal does not make clear what will happen in the future, we will maintain our decision not to invest," Leif Johansson told France's Le Monde newspaper.
Reuters•7 days agoNovo Nordisk hires AstraZeneca executive to revive struggling biopharma unit
Novo Nordisk (NOVOb.CO) is in advanced talks to acquire assets to bolster its struggling biopharma business, its chief executive said on Monday after the drugmaker announced it had hired an AstraZeneca executive to head the unit. Novo, best known for its diabetes drugs, has been looking for biopharma assets after losing out to French rival Sanofi (SASY.PA) in the chase for Belgian biotech company Ablynx (ABLX.BR) in January. Sales at Novo's biopharma unit fell 16 percent last year and the Danish drugmaker said on Monday it has hired AstraZeneca's (AZN.L) head of cardiovascular and metabolic diseases, Ludovic Helfgott, to head the business from next April.
- Zacks•10 days ago
3 Large-Cap Pharma Stocks Performing Better Than Industry
We focus on three large-cap pharma stocks that are outperforming the industry on the back of their diverse portfolio.
- Zacks•10 days ago
J&J (JNJ) Gets FDA Approval for Xarelto Label Expansion
Johnson & Johnson's (JNJ) Xarelto gets FDA approval for reducing risk of major cardiovascular events in chronic coronary or peripheral artery disease patients.
- Zacks•11 days ago
Merrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts
Merrimack (MACK) focuses on the development of its two early-stage pipeline candidates, MM-121 and MM-310. The candidates have been progressing well and are imperative to the company's growth.
- Motley Fool•11 days ago
3 Dividend Stocks That Pay You Better Than Pepsi Does
Before you add Pepsi to your income portfolio, you might want to consider these three high-dividend-paying stocks.
- Market Realist•11 days ago
Analysts’ Estimates and Ratings for Novartis in October
Novartis’s (NVS) revenue is mainly driven by the strong performance of its Innovative Medicines segment, while Sandoz and Alcon also contribute to the company’s overall growth.
- Market Realist•12 days ago
A Closer Look at Novartis’s Innovative Medicines Segment
Novartis’s (NVS) Innovative Medicines segment includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology.
- Market Realist•13 days ago
How Novartis’s Businesses Have Been Performing
Novartis’s (NVS) business is separated into three segments: Innovative Medicines, the prescription medicines business Sandoz, the generics business Alcon, the eye care business
- Zacks•13 days ago
Top Research Reports for JPMorgan, American Express & FedEx
Top Research Reports for JPMorgan, American Express & FedEx
- Market Realist•17 days ago
GW Pharmaceuticals: Q3 Performance, Q4 Estimates
GW Pharmaceuticals (GWPH) is a leader in the development of plant-derived cannabinoid therapeutics. GW Pharmaceuticals reported EPS of -$1.26 on revenues of $3.46 million in the third quarter. It was a 10.2% revenue growth year-over-year.
- Market Realist•18 days ago
Novartis ADR’s Performance and Revenue Estimates for Q3 2018
Headquartered in Basel, Switzerland, Novartis (NVS) specializes in research and development, manufacturing, and marketing of a broad range of healthcare products. The company’s three segments are Innovative Medicines, Sandoz, and Alcon. Sandoz is Novartis’s generics business, and Alcon is its eye care business.
